摘要
目的:研究"扶肺解毒方"联合"安罗替尼"治疗晚期非小细胞肺癌的临床疗效及其毒副反应。方法:纳入2018年5月-2019年8月我科收治的48例Ⅳ期非小细胞肺癌患者,随机分为治疗组和对照组,其中治疗组24例采用口服中药汤剂"扶肺解毒方"联合口服靶向药物"安罗替尼"治疗;对照组24例单独口服"安罗替尼"治疗。随访时间为2个月,观察采取不同治疗方案的两组患者近期的临床疗效及其毒副反应。结果:治疗组和对照组疾病控制率分别为87.5%和75%,治疗组和对照组KPS评分治疗前后分别为68.33±8.50、69.58±8.89和84.58±9.20、79.17±9.97,差异有统计学意义(P<0.05);治疗组咳嗽、咳痰、乏力等改善更为明显,差异有统计学意义(P<0.05)。治疗组和对照组>1级蛋白尿、手足皮肤反应、高血压发生率分别为4.1%、4.1%、8.3%和20.8%、25%、25%,差异有统计学意义(P<0.05)。结论:"扶肺解毒方"联合"安罗替尼"治疗晚期非小细胞肺癌可以减轻"安罗替尼"的近期毒副反应,且能提高"安罗替尼"治疗晚期肺癌的近期疗效。
Objective: To study the clinical efficacy and side effects of Fufei Jiedu Formula combined with Anlotinib in the treatment of advanced non-small cell lung cancer. Methods: 48 cases of Ⅳ stage non-small cell lung cancer were randomly divided into the treatment group(n=24) and the control group(n=24). The control group was treated with Anlotinib;on which basis, the treatment group was also treated with Fufei Jiedu Formula. The follow-up duration was 2 months to observe the short-term clinical efficacy and side effects of the two different therapies in the two groups. Results: The rate of disease control was 87.5% in the treatment group and 75% in the control group. The KPS scores were 68.33±8.50 and 69.58±8.89 in the treatment group and 84.58±9.20 and 79.17±9.97 in the control group before and after the treatment respectively, with statistical difference(P<0.05). The improvements of cough, sputum and fatigue were more obvious in the treatment group than those in the control group(P<0.05). The incidence of more than grade 1 proteinuria, hand-foot skin reaction and hypertension were 4.1%, 4.1% and 8.3% in the treatment group and 20.8%, 25% and 25% in the control group respectively, with statistical difference(P<0.05). Conclusion: Fufei Jiedu Formula combined with Anlotinib can alleviate the short-term side effects and improve the short-term efficacy of Anlotinib in the treatment of advanced lung cancer.
作者
慈雪萍
孙庆明
董皖辉
CI Xueping;SUN Qingming;DONG Wanhui(Department of Oncology,Liu’an Hospital of TCM,Liu’an 237000,China)
出处
《中医药学报》
CAS
2020年第9期42-45,共4页
Acta Chinese Medicine and Pharmacology
关键词
扶肺解毒方
安罗替尼
非小细胞肺癌
Fufei Jiedu Formula
Anlotinib
Non-small cell lung cancer
作者简介
慈雪萍(1985-),女,硕士,主治医师,主要从事肿瘤内科临床工作。
